Clinical characteristics and prognosis of antibody-mediated autoimmune encephalitis: A single-center cohort study in Liuzhou, China
Open Access
- 10 July 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (28) , e49565
Abstract
This retrospective observational study primarily aims to analyze the clinical characteristics and prognosis of patients with antibody-mediated autoimmune encephalitis (AE) in Liuzhou, China. We retrospectively reviewed the medical records of 32 patients diagnosed with acute AE between January 1, 2017, and August 31, 2024, for the following parameters: clinical features, results of laboratory and imaging studies, treatment, and clinical outcomes. Anti-N-methyl-d-aspartate receptor encephalitis was the most prevalent subtype (50%, 16/32). Other subtypes included glial fibrillary acidic protein astrocytopathy encephalitis (12.5%, 4/32), anti-myelin oligodendrocyte glycoprotein encephalitis (12.5%, 4/32), anti-leucine glioma inactivating protein 1 encephalitis (6.3%, 2/32), anti-GAD65 encephalitis (6.3%, 2/32), anti-GABABR encephalitis (6.3%, 2/32), and anti-contactin-associated protein-like 2 encephalitis (6.3%, 2/32). The most common prodromal manifestation were fever or influenza-like illness (56.25%). The primary clinical manifestations included seizures (25.68%), psychiatric and behavioral disorders (17.57%), disturbances in consciousness (9.46%), and dyssomnia (9.46%). Pneumonia, observed in 43.75% (14/32) of patients, was associated with older age ( P = .017), higher intensive care unit admission rates ( P = .042), increased need for mechanical ventilation ( P = .002), and worse modified Rankin Scale scores at diagnosis ( P = .005). Immunotherapy led to clinical improvement in most cases (78.13%), and these patients achieved favorable outcomes (modified Rankin Scale ≤ 2; median follow-up 37 months). In conclusion, the AE characteristics in our single-center retrospective study were consistent with previous findings. The proportion of anti- N -methyl- d -aspartate receptor encephalitis was the highest. Once AE is diagnosed, immunotherapy should be initiated promptly to reduce disease severity and improve outcomes. In clinical practice for AE management, emphasis should be placed on pneumonia prevention and treatment to reduce the rate of intensive care unit admission and mechanical ventilation and shorten the length of hospitalization.Keywords
Funding Information
- Guangxi Zhuang Autonomous Region Health and Family Planning Commission Projects (Z-B20232008)
This publication has 42 references indexed in Scilit:
- Autoimmune encephalitis epidemiology and a comparison to infectious encephalitisAnnals of Neurology, 2018
- The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitisNature Reviews Neurology, 2017
- Autoimmune Glial Fibrillary Acidic Protein AstrocytopathyJAMA Neurology, 2016
- A clinical approach to diagnosis of autoimmune encephalitisThe Lancet Neurology, 2016
- Autoimmune encephalitis as differential diagnosis of infectious encephalitisCurrent Opinion in Neurology, 2014
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- Antibodies and neuronal autoimmune disorders of the CNSJournal of Neurology, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratomaAnnals of Neurology, 2007